We are live on ! Find out more

Femasys

FEMY

Market cap $24.5M

2.93 USD

-0.05

1.68%

At close Updated Sep 8, 10:07 AM EDT

1 day

-1.68%

5 days

-12.28%

1 month

23.63%

3 months

-45.64%

6 months

-71.93%

Year to date

-76.98%

1 year

-61.95%

5 years

-98.07%

10 years

-98.78%

About: Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Employees: 54

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 16.7%

Neutral 83.3%

Negative 0%

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue ® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to introduce its female and male fertility diagnostics, FemVue and SpermVue™, together with FemaSeed Complete, an in-office intratubal insemination solution designed as a first-line fertility treatment, within UNC Health OB/GYN practice locations. “We launched our OB/GYN commercial initiative at the ACOG Annual Clinical & Scientific Meeting on May 1st with the goal of bringing fertility evaluation and treatment earlier in the care pathway, and we are thrilled that a leading academic health system such as UNC Health is making these important technologies available within its OB/GYN practices,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys.

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

The U.S. Food and Drug Administration (FDA) on Wednesday authorized the modular premarket approval application pathway for FemBloc, a non-surgical permanent birth control technology.

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents

-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the issuance of patents in the United States and key international markets that expand intellectual property protection for the blended polymer component of FemBloc, the Company's non-surgical permanent birth control technology. These patents broaden and extend FemBloc's global intellectual property protection, complementing existing patents covering its delivery system and further strengthening the technology's competitive position in a highly regulated market with rigorous clinical and regulatory requirements.

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents

Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

-- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has entered into a securities purchase agreement (the “Purchase Agreement”) for a $30 million private placement with certain accredited investors. The financing was led by new institutional investor Nantahala Capital, with participation from additional new healthcare-focused funds, including Rosalind Advisors, Inc., as well as members of Femasys' management team. The private placement is subject to customary closing conditions and is expected to close on or around August 10, 2026.

Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

Femasys Regains Compliance with Nasdaq Listing Requirements

ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today that it received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) confirming the Company has regained compliance with Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing and that the matter is now closed.

Femasys Regains Compliance with Nasdaq Listing Requirements

Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter

-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- -- New catheter complements FemVue® and supports streamlined in-office fertility evaluation --

Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- -- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices --

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the first revenue-generating commercial use of its fertility portfolio in the OBGYN setting, led by FemaSeed as a first-line infertility treatment. The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women's primary physician, where earlier intervention can improve access and outcomes.

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- -- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval --

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

See News Rankings

Price charts implemented using Lightweight Charts™